VivoSeq
Psychiatry

Substance Use Disorder (SUD)

0

Pipeline Programs↗

5

Active Trials↗

0

Companies Involved↗

Substance Use Disorder (SUD) is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

14/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Not yet recruiting3 · 43%
Recruiting2 · 29%
Completed1 · 14%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

Assessment of Safety and Feasibility of Focused Ultrasound (FUS) Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Substance Use Disorder (SUD)
Recruiting·SSunnybrook Health Sciences Centre·Preclinical·NCT07684976·20 enrolled
Substance Use in Pregnant People - Optimizing Retention in Treatment by Maximizing Opportunities for Management
Recruiting·WWashington University School of Medicine·Preclinical·NCT07104123·40 enrolled
A Preliminary Study on the Effectiveness of a Psychosocial Treatment Program (Emotion Regulation Program) for Substance Use Disorders
Not yet recruiting·TThe Catholic University of Korea·Preclinical·NCT07698821·20 enrolled
A Preliminary Study on the Effectiveness of a Psychosocial Treatment Program (Craving Management and Alternative Behavior Enhancement Program) for Substance Use Disorders
Not yet recruiting·TThe Catholic University of Korea·Preclinical·NCT07698808·20 enrolled
A Preliminary Study on the Effectiveness of a Psychosocial Treatment Program (First Step Program) for Substance Use Disorders
Not yet recruiting·TThe Catholic University of Korea·Preclinical·NCT07658963·20 enrolled
Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Completed·NNYU Langone Health·N/A·NCT00953862·18 enrolled
Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition
Terminated·UUniversity of Colorado, Denver·Phase 2/3·NCT04847921·11 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)